The article discusses the trial for the antisepsis drug Xigris, activated protein C on several people for its approval. Indiana-based drug company, Eli Lilly & Co. had already withdrawn this drug from the global market in October 2011 due to the failure of prowess-shock trial. Xigris failed to reduce mortality in patients with septic shock in the Prowess-Shock trial.